Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Interim analysis after 3 months of AML patients treated with venetoclax + azacitidine – first effectiveness and safety data from the prospective real world vero study

Blood (2025) 146 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2025-3384

Published: 2025

Journal Articles

Treatment initiation pattern, ramp-up measures and management of AML patients treated in real life in Italy with venetoclax+azacitidine - first interim analysis of the prospective vero study

Blood (2025) 146 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2025-3383

Published: 2025

Journal Articles

First interim analysis of venetoclax real-world observational study on newly-diagnosed AML patients in Italy (VERO): Focus on patient and diseases characteristics and quality of life at baseline

Blood (2025) 146 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2025-5159

Published: 2025

Journal Articles

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

Blood (2025) 146 (Supplement 1): 6967.

https://doi.org/10.1182/blood-2025-6967

Published: 2025

Journal Articles

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Blood (2025) 146 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2025-1662

Published: 2025

Journal Articles

Treosulfan Plus Fludarabine (TTF10) As Preparative Regimen before Haploidentical Trasplant in Elderly Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 7294.

https://doi.org/10.1182/blood-2024-208595

Published: 2024

Journal Articles

Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Francesco Angotzi, Erika Borlenghi, Chiara Sartor, Maria Benedetta Giannini, Giovanni Marconi, Edoardo Tamellini, Mauro Turrini, Federica Loscocco, Ernesta Audisio, Vincenzo Federico, Calogero Vetro, Andrea Visentin, Carmela Gurrieri, Livio Trentin, Felicetto Ferrara, Federica Lessi

Blood (2024) 144 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2024-209605

Published: 2024

Journal Articles

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Blood (2023) 142 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2023-190091

Published: 2023

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

BCL-2 and BCL-X L Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study

Blood (2022) 140 (Supplement 1): 8979–8980.

https://doi.org/10.1182/blood-2022-163716

Published: 2022

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

Efficacy and Safety Of Melphalan and Prednisone In Combination With Thalidomide, Bortezomib Or Lenalidomide In Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients: A Single Center Experience

Fabiana Gentilini, MD, Vincenzo Federico, MD, Eleonora Russo, MD, Paola Finsinger, MD, Roberto Ricci, Patrizia Del Bianco, Francesca Prestanicola, Moira Cappelloni, Maria Letizia Vallone, Robin Foa, MD, Maria Teresa Petrucci, MD

Blood (2013) 122 (21): 5375.

https://doi.org/10.1182/blood.V122.21.5375.5375

Published: 2013

Journal Articles

Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age

Blood (2013) 122 (21): 539.

https://doi.org/10.1182/blood.V122.21.539.539

Published: 2013

Journal Articles

Clinical Characteristics and Predictive Factors of Peripheral Neurophaty in Multiple Myeloma Patients Treated with Bortezomib and/or Imids

Vincenzo Federico, MD, Russo Eleonora, MD, PhD, Andrea Truini, MD, Anna Levi, MD, PhD, Fabiana Gentilini, MD, Giulia Biagioli, Caterina Leoni, MD, Robin Foà, MD, Maria Teresa Petrucci, MD

Blood (2012) 120 (21): 4056.

https://doi.org/10.1182/blood.V120.21.4056.4056

Published: 2012

Journal Articles

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

Roberto Latagliata, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Antonietta Ferretti, Giuseppina Loglisci, MD, Michelina Santopietro, Vincenzo Federico, Rosa De Cuia, Daniela Diverio, Mauro Nanni, PhD, Marco Mancini, Giuliana Alimena

Blood (2011) 118 (21): 3783.

https://doi.org/10.1182/blood.V118.21.3783.3783

Published: 2011

Journal Articles

MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Roberto Latagliata, Michelina Santopietro, Adriano Salaroli, Alessandra Serrao, Gioia Colafigli, Agostino Tafuri, Giuliana Alimena

Blood (2011) 118 (21): 3793.

https://doi.org/10.1182/blood.V118.21.3793.3793

Published: 2011

Journal Articles

Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia

Massimo Breccia, Roberto Latagliata, MD, Fabio Stagno, Antonella Gozzini, Elisabetta Abruzzese, Francesco Albano, Vincenzo Federico, Federica Sorà, Paolo Vigneri, Giuseppina Loglisci, Malgorzata Trawinska, Simona Sica, Giorgina Specchia, Valeria Santini, MD, Giuliana Alimena

Blood (2010) 116 (21): 2270.

https://doi.org/10.1182/blood.V116.21.2270.2270

Published: 2010

Journal Articles

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.

Federica Cavallo, MD, Alessandra Larocca, MD, Maria Teresa Petrucci, MD, Vincenzo Federico, MD, Antonietta Pia Falcone, MD, Grazia Sanpaolo, MD, Letizia Canepa, MD, Monica Crugnola, MD, Mario Boccadoro, MD, Antonio Palumbo, MD

Blood (2009) 114 (22): 2864.

https://doi.org/10.1182/blood.V114.22.2864.2864

Published: 2009

Journal Articles

Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.

Giacomo Salvatore Morano, Caterina Mercanti, Vincenzo Federico, MD, Angela Matturro, Alessandra Micozzi, Roberto Latagliata, MD, Massimo Breccia, Corrado Girmenia, Gregorio Antonio Brunetti, Paola Berneschi, Massimo Giampaoletti, Robin Foà, Giuliana Alimena

Blood (2009) 114 (22): 4545.

https://doi.org/10.1182/blood.V114.22.4545.4545

Published: 2009

Journal Articles

Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study

Maria Teresa Petrucci, Elisabetta Calabrese, Anna Levi, Vincenzo Federico, Michela Ceccolini, Rita Rizzi, Alessandro Gozzetti, Patrizia Falco, Maria Caterina Cavallo, Simone Gerzelli, Mario Boccadoro, Francesco Lauria, Vincenzo Liso, Michele Cavo, Robert Foa

Blood (2008) 112 (11): 2393.

https://doi.org/10.1182/blood.V112.11.2393.2393

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Interim analysis after 3 months of AML patients treated with venetoclax + azacitidine – first effectiveness and safety data from the prospective real world vero study

Treatment initiation pattern, ramp-up measures and management of AML patients treated in real life in Italy with venetoclax+azacitidine - first interim analysis of the prospective vero study

First interim analysis of venetoclax real-world observational study on newly-diagnosed AML patients in Italy (VERO): Focus on patient and diseases characteristics and quality of life at baseline

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Treosulfan Plus Fludarabine (TTF10) As Preparative Regimen before Haploidentical Trasplant in Elderly Patients with Acute Myeloid Leukemia

Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

BCL-2 and BCL-X L Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study

Efficacy and Safety Of Melphalan and Prednisone In Combination With Thalidomide, Bortezomib Or Lenalidomide In Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients: A Single Center Experience

Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age

Clinical Characteristics and Predictive Factors of Peripheral Neurophaty in Multiple Myeloma Patients Treated with Bortezomib and/or Imids

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.

Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.

Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only